

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported: May 26, 2005)

ReGen Biologics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

000-20805

(Commission
File Number)

23-2476415

(IRS Employer
Identification No.)

509 Commerce Street, East Wing, Franklin Lakes, NJ

(Address of principal executive offices)

07417

(Zip Code)

Registrant's telephone number, including area code **(201) 651-5140**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On May 26, 2005, ReGen Biologics, Inc. (the "Company") issued a press release announcing that it will be hosting an evening event during the EFORT Congress in Lisbon at 6:00 p.m. on June 6th 2005 for surgeons currently familiar with the ReGen® CMI or those who would like to obtain more information.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, nor should it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements And Exhibits.

99.1 Press Release of ReGen Biologics, Inc. dated May 26, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGEN BIOLOGICS, INC.

By: /s/ Brion D. Umidi
Name: Brion D. Umidi
Title: Senior Vice President and Chief Financial Officer

Dated: May 26, 2005

**REGEN BIOLOGICS AG TO HOST JUNE 6, 2005 EVENING EVENT AT EFORT
CONGRESS IN LISBON FOR SURGEONS INTERESTED IN REGEN® CMI**

Company to Review Results of 5 Year Feasibility Study

APPENZEL, SWITZERLAND, May 26, 2005—ReGen Biologics, AG, a wholly owned subsidiary of ReGen Biologics, Inc., (OTC:RGBI) an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets, announced today that that the company will be hosting an evening event during the EFORT Congress in Lisbon at 6:00 p.m. on June 6th 2005 for surgeons currently familiar with the ReGen® CMI or those who would like to obtain more information.

ReGen Biologics, AG is inviting all interested surgeons to participate. During this event, the CMI five (5) year follow-up data from the feasibility study will be presented. These data have been published as the lead article in the May 2005 issue of the peer-reviewed journal *Arthroscopy*. Clinical data including serial magnetic resonance imaging and arthroscopic examinations demonstrate the benefit of the CMI for these patients and provide evidence that a substantial amount of meniscus tissue is regained compared to a partial meniscectomy, which is the alternative treatment.

If you would like to attend this event, please R.S.V.P. to ReGen Biologics AG or contact one of the two European contacts below.

For more information about marketing and distribution in Europe, please contact:

Thomas B. Fischer
ReGen Biologics AG
Feldstrasse 11
CH 9050 Appenzell
+41 (0)79 500 79 54
thomas.fischer@regenbio.com

Evelyne M. Hasler
ReGen Biologics AG
Feldstrasse 11
CH-9050 Appenzell
+41 (0)79 820 62 42
evelyne.hasler@regenbio.com

About ReGen Biologics AG:

ReGen Biologics AG is a wholly-owned subsidiary of ReGen Biologics Inc. The Swiss subsidiary was founded in 2005 and will lead the European marketing and distribution for the CMI and other ReGen Biologics, Inc. products.

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's first product using its patented core technology is the CMI, which uses the body's own healing process to grow new tissue in the meniscus, and restore activity levels for patients with meniscus loss. The Company's Multicenter Pivotal Clinical Trial is the largest clinical trial ever conducted involving the human meniscus. The manufacturing module was submitted to the FDA in Q3 2004. The Company expects to conclude the PMA submission with the filing of the CMI clinical module in the second half of 2005.

exv99w1

ReGen is headquartered in Franklin Lakes, NJ and manufactures the CMI in its ISO Certified facility located in Redwood City, CA.

For more information on ReGen, visit www.regenbio.com, call (201) 651-5140, or email info@regenbio.com.

Contact:

Brion Umidi
ReGen Biologics, Inc.
Senior Vice President
Chief Financial Officer
(201) 651-3515
bumidi@regenbio.com

Al Palombo
Cameron Associates
Investor Relations
(212) 245-8800 Ext. 209
al@cameronassoc.com